Peroxisome Proliferator-Activated Receptor-γ Gene Expression and Its Association with Oxidative Stress in Patients with Metabolic Syndrome

Mehdi Hatami¹, Massoud Saidijam², Reza Yadegarzari², Shiva Borzuei³, Alireza Soltanian⁴, Marzieh Safi Arian¹, and Mohammad Taghi Goodarzi²,*  
¹Department of Clinical Biochemistry, Medical School, ²Research Center for Molecular Medicine, ³Department of Internal Medicine, Medical School, ⁴Department of Biostatistics, Health School, Hamadan University of Medical Sciences, Hamadan, Iran

Regulation of the peroxisome proliferator-activated receptor-γ (PPAR-γ) gene plays an important role in controlling the metabolism of lipids and inflammatory processes. Therefore, it can be associated with the pathogenesis of metabolic syndrome (MetS). The purpose of this study was to determine the expression of this gene in peripheral blood mononuclear cells (PBMC) in patients with metabolic syndrome. Using real-time polymerase chain reaction (PCR), mRNA expression of PPAR-γ was found in PBMC from 37 subjects with MetS and 30 healthy controls. Serum levels of glucose and lipid profiles were measured. The total antioxidant capacity (TAC) was measured using the ferric reducing ability of plasma (FRAP) test. Malondialdehyde (MDA) was determined using a fluorimetric method. Total oxidant status (TOS) in serum was assayed according to oxidation of ferric to ferrous in the presence of methyl orange. Super oxide dismutase (SOD) activity was measured using a Randox kit. Expression of PPAR-γ gene was significantly increased in patients with MetS compared to the control subjects (p=0.002). There was no difference in serum levels of TAC, MDA and SOD between the two study groups, but a significant difference was observed in the TOS (p=0.03). Serum levels of triglycerides and glucose were significantly higher in subjects with MetS. According to the results of our study, an increase in the expression of PPAR-γ in subjects with MetS indicated a possible role of PPAR-γ in the pathogenesis of this disease.

Key Words: Gene Expression; Metabolic Syndrome; Oxidative Stress; Peroxisome Proliferator-Activated Receptor γ

INTRODUCTION

Metabolic syndrome (MetS) is a cluster of various disorders which are characterized by the impairment of glucose tolerance or hyperglycemia, abdominal obesity, high blood pressure and dyslipidemia.¹ Obesity and MetS are related to an increased risk of cardiovascular disease, type 2 diabetes mellitus, hypertension, hyperlipidemia, mortality and morbidity in certain cancers.² These conditions are characterized by an altered oxidative/antioxidant status and by subclinical inflammation; both are responsible for the development of atherosclerosis. Recently there has been a focused interest on the role of oxidative stress in the commencement of the MetS and insulin resistance.³,⁴ Increase in the synthesis of reactive oxygen species (ROS) and/or failure of the defenses against the ROS cause MetS which lead to an increase in oxidative stress.⁵ Under normal physiological conditions, different antioxidant systems can eliminate or inactivate ROS and free radicals. Superoxide dismutase (SOD) enzymatically converts superoxide anions (O₂⁻) to hydrogen peroxide and subsequently hydrogen peroxide is disposed by the enzyme glutathione peroxidase (GSH-Px).⁶ On the other hand, catalase, a peroxisomes exclusive enzyme, detoxifies hydrogen peroxide. Furthermore, there are various molecules which eliminate or inactivate ROS-producing free
radicals; endogenous molecules like uric acid and albumin and exogenous antioxidants derived from diet like ascorbic acid and vitamin E. The sum of endogenous and food-derived antioxidants represents the total antioxidant capacity (TAC) of the extracellular fluids.

The members of the superfamily of nuclear hormone receptors, peroxisome proliferator-activated receptors (PPARs), are ligand-dependent transcription factors which are predominantly expressed in adipose tissue and are known to be involved in differentiation of adipocyte and as the regulator of adipogenesis. Lower levels of PPAR-γ are expressed in other tissues such as skeletal muscle and liver tissues, which are the major target tissues for insulin. The expression of PPAR-γ has been shown in human peripheral blood mononuclear cells (PBMC), such as macrophages and monocytes, where it plays an important role in the regulation of the inflammatory processes like down regulation of proinflammatory mediators in macrophages.

The anti-inflammatory effect of PPAR-γ is shown through its inhibitory effect on the production of inflammatory cytokines, such as tumor necrosis factor-α in the monocytes and nuclear factor kappa B (NF-kB) as well. A hypermetabolic state is associated with alterations in oxidative metabolism, increased production of free radicals and oxidative stress, and finally the acute phase response (APR). In adipose tissue, recently the APR has been shown to down-regulate PPAR-γ, which can be expected because PPAR-γ is generally anti-inflammatory and improves insulin sensitivity.

Since PPAR-γ shows a role in inflammatory processes, it can be associated with the pathogenesis of MetS. The purpose of this study was to determine the expression of PPAR-γ gene in PBMC in patients with metabolic syndrome compared with the healthy control group. Determination of a possible correlation between the expression of the PPAR-γ gene and the anti-oxidant parameters in both normal and MetS groups was another aim in this study.

MATERIALS AND METHODS

1. Patients

Thirty healthy subjects who did not meet the criteria for metabolic syndrome and 37 patients with metabolic syndrome participated in this study. MetS was diagnosed when the candidates had at least three positive criteria out of the following: 1. Systolic blood pressure (SBP) ≥ 130 mmHg and diastolic blood pressure (DBP) ≥ 85 mmHg. 2. Fasting blood sugar (FBS) ≥ 6.05 mmol/L or 100 mg/dL. 3. Waist circumference ≥ 90 cm in women, ≥ 85 cm in men. 4. High-density lipoprotein cholesterol (HDL-C) ≤ 1.8 mmol/L. 5. Triglycerides (TG) ≥ 150 mg/dL. Diabetic patients and subjects having blood hypertension, liver, kidney or thyroid disease were excluded from the study. Subjects who were on antihyperlipidemic medications as well as pregnant women were also excluded. Overnight fasting blood samples of all the participants were taken and collected in three tubes for serum, plasma, using ethylenediamine tetra-acetic acid (EDTA), and PBMC preparation. Plasma and serum were separated by centrifugation (1,000 g, 5 min). Height, weight, waist circumference, systolic and diastolic blood pressures were also measured in all participants. The body mass index was calculated as well. The protocol of the study was approved by the Ethics Committee of Hamadan University of Medical Sciences, Hamadan, Iran, in accordance with the Helsinki Declaration. Written informed consent was acquired from all participants.

2. Measurement of biochemical factors

Serum samples were used to assess fasting blood glucose, total cholesterol, TG, high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) levels. Enzymatic calorimetric kits were used to measure serum levels of total cholesterol; triglyceride and blood glucose (ParsAzmun, Iran). The homogeneous enzymatic calorimetric test was used to measure the serum levels of LDL-C and HDL-C.

3. Isolation of peripheral blood mononuclear cell (PBMC), RNA extraction and cDNA synthesis

The PBMCs were isolated from anticoagulant-treated blood samples using the Ficoll standard density gradient centrifugation (1,000 g; 5 min). Total RNA from PBMC samples was extracted using the column separation method. The isolated RNA was treated with DNase I (Fermentas Inc., Vilnius, Lithuania) to remove any possible DNA contamination; it was quantified at 260 nm using a nanodrop spectrophotometer (Eppendorf, Hamburg, Germany). The integrity of the RNA was verified by examining a optical density absorption ratio OD260 nm/OD280 nm that was between 1.8 and 2.0. The c-DNA was obtained from 1 µg of total sample of RNA. The obtained c-DNA was used as a template for real-time quantitative PCR.

4. Real-time quantitative PCR analysis

A quantitative, real-time PCR using a qPCR™ Green Master Kit for SYBR Green IW (Jena Bioscience, Gmbh, Germany) was developed for detecting relative mRNA levels of PPAR-γ in PBMCs, in real-time PCR detection system (Bio-Rad Laboratories, USA). Relative expression levels of PPAR-γ transcription were normalized to RNA loading for each sample using 18s rRNA. Specific primers for all genes were designed using AlleleID7.6 software (version 7.6).

Sequences of sense and antisense primers for the PPAR-γ and reference gene (18s rRNA) are shown in Table 1. The PCR reactions were performed on a final volume of 20 µL containing 1 µL cDNA, 7 µL deionized water, sense and antisense primers (1 µL of each) and 10 µL SYBR Green IW. The reactions were performed (in triplicate) with the following settings: 10 minutes of pre-incubation at 95°C followed by 40 cycles for 30 seconds at 95°C and 30 seconds at 72°C. A reaction without c-DNA was performed in parallel as a negative control.

Using the standard curve, a relative number of copies was obtained and normalized to values which were ob-
Table 1. Primers used in amplification of PPAR-γ and 18s rRNA genes

| Gene       | Primer | Sequence of primer | Primer length | GC% | Tm | Product length |
|------------|--------|--------------------|---------------|-----|----|----------------|
| PPARγ      | F      | CTTCTGGATTTCATATGGAG | 21            | 42.5 | 49.5 | 129            |
|            | R      | AAGGTTGCTCTGCTACATCAT | 20            | 45   |     |                |
| 18s rRNA   | F      | GTAACCCGTGTAGACCGCAATT | 20            | 54.8 | 64.5 | 151            |
|            | R      | CCATCCATCGGTAGTACCG | 20            | 54.4 |     |                |

F: forward primer, R: reverse primer, Tm: melting temperature, GC%: percentage of guanosine and cytosine nucleotides.

Table 2. Anthropometric and biochemical parameters in metabolic syndrome patients and healthy control subjects

| Parameters         | MetS               | Control            | p value |
|--------------------|--------------------|--------------------|---------|
| Age (years)        | 49.83±12           | 43.36±13           | 0.26    |
| Weight (kg)        | 80.70±14           | 68.23±11           | 0.001   |
| BMI (kg/m²)        | 29.83±4.5          | 24.93±4.03         | 0.001   |
| Waist (cm)         | 105.27±13          | 92.30±11           | 0.001   |
| Systolic pressure  |                    |                    |         |
| (mmHg)             | 127±14             | 118±9              | 0.002   |
| Diastolic pressure |                    |                    |         |
| (mmHg)             | 82±8.9             | 80±4.5             | 0.15    |
| FBS (mg/dL)        | 105±21             | 92±8               | 0.001   |
| tChol (mg/dL)      | 204±57             | 192±44             | 0.35    |
| TG (mg/dL)         | 187±66             | 142±57             | 0.029   |
| HDL-c (mg/dL)      | 43±9.2             | 47±8.6             | 0.146   |
| LDL-c (mg/dL)      | 129±35             | 117±37             | 0.182   |

Data are Mean±SD. MetS: Metabolic syndrome, BMI: body mass index, FBS: fasting blood sugar, tChol: total cholesterol, TG: triglycerides, HDL-c: high density lipoprotein cholesterol, LDL-c: low density lipoprotein cholesterol.

Table 3. Different parameters of oxidative stress in metabolic syndrome patients and controls

| Parameter          | MetS (N=37)         | Control (N=30)    | p value |
|--------------------|---------------------|-------------------|---------|
| TAC (mmol/mL)      | 0.40±0.09           | 0.38±0.08         | 0.34    |
| TOS (mmol/mL)      | 0.84±0.43           | 0.65±0.29         | 0.03    |
| MDA (μmol/mL)      | 1.85±1.4            | 1.6±1.1           | 0.63    |
| SOD (U/mL)         | 0.33±0.49           | 0.53±0.75         | 0.2     |

Data are expressed as Mean±SD. MetS: Metabolic syndrome, TAC: total antioxidant capacity, TOS: total oxidant status, SOD: superoxide dismutase activity, MDA: malondialdehyde.

RESULTS

Comparisons of the baseline SBP and DBP, waist circumference, body mass index (BMI), and biochemical parameters between the studied groups are presented in Table 2. There were significant differences in the values for weight (p=0.001), body mass index (BMI) (p=0.001), waist circumference (p=0.001) and SBP (p=0.002) between the two study groups despite no significant difference in DBP. Comparing biochemical parameters showed higher levels of fasting blood sugar (FBS) (p=0.001) and TG (p=0.029) in the subjects with MetS. There was no significant difference in total cholesterol (tChol), HDL-C and LDL-C between the study groups.

While none of the subjects in the control group had the criteria of MetS, some components of MetS were observed in some cases; waist circumference, HDL-C, TG and FBS in 17%, 13%, 10%, and 10% of controls subjects respectively. The levels of the various oxidative stress factors are shown in Table 3. No significant differences in the levels of TAC, MDA and SOD were found between the two groups. The only parameter which had a significantly higher level in MetS group was TOS (p=0.03). Fig. 1 illustrates the relative expression of PPAR-γ gene which is significantly lower in patients group compared to the healthy control group (p=0.002), which indicates a higher expression in MetS subjects. To further analyze the relative gene expression of PPAR-γ, the fold change of this gene in MetS group was calculated using the 2^−ΔΔCt formula. The obtained results showed a 9.5-fold higher expression of the PPAR-γ gene in the MetS group.

6. Statistical analyses

Data analysis was carried out using the SPSS 18.0 software package (SPSS Inc., Chicago, IL, USA). Independent-samples-test was used to measure the differences in studied parameters between two groups. All experimental data was presented as the mean±standard deviation (SD). The Spearman correlation coefficient was calculated to estimate the correlations between variables. Values were considered to be statistically significant when the p<0.05.
of MetS was also determined. PPAR-γ gene expression in the MetS group showed a negative correlation with HDL-C ($r = -0.35$, $p = 0.03$) and a positive correlation with TG ($r = 0.42$, $p = 0.026$). No statistically significant correlation was observed between PPAR-γ gene expression and the other components of MetS in both groups. Furthermore, there was no correlation between expression of the PPAR-γ gene and the anti-oxidant parameters in both normal and MetS groups.

**DISCUSSION**

In this study we evaluated the expression of the PPAR-γ gene in MetS subjects. We also examined any association between MetS, serum lipid variation, and oxidative state. MetS is a multi-factorial disorder and its causes have not been precisely determined. The higher expression of PPAR-γ was observed in MetS subjects compared to healthy control group. The PPAR-γ is a ligand-activated transcription factor belonging to the nuclear receptor superfamily which plays a critical role in the metabolism of lipids and glucose. It enhances macrophage lipid uptake as well as lipid export. It has been shown that PPAR-γ can be expressed in both adipocyte and human PBMCs and the higher expression of this gene was seen after consumption of a high-fat meal in healthy individuals. Anti-inflammatory properties of PPAR-γ have been extensively reviewed in other studies.

In obesity, production of inflammatory cytokines TNFα, IL-1β and IL-6 result in a wide range of metabolic changes. It has been shown that TNFα and IL-1 directly decrease the levels of PPAR-γ.

We found higher levels of PPAR-γ expression in the PBMCs of patients with MetS, which was associated with a significant higher plasma level of TG. Garcia-Fuentes et al. studied PPAR-γ expression in PBMCs in morbidly obese persons. They found that the reduction in the expression of PPAR-γ is correlated with the increase in free fatty acids.

The alteration in oxidative metabolism is accompanied by an increase in the production of free radicals and oxidative stress parameters that may induce a hypermetabolic state and APR. There is evidence that PPAR-γ ligands can increase the expression and activity of Cu/Zn SOD and decrease the expression of the NADPH oxidase subunit in vascular-endothelial cells, in vitro. The relation between this gene and antioxidant parameters was examined in our study. No correlation was observed between the levels of PPAR-γ and antioxidant parameters. These results did not support our hypothesis that PPAR-γ affects these parameters. Higher expression of the PPAR-γ gene, which was observed in the MetS group in this study, was similar to the findings in the study by Macias-Gonzalez et al. In their study, PPAR-γ expression was higher in patients compared to healthy subjects. However, down-regulation of PPAR-γ was observed in MetS patients after a fat overload compared with baseline level. In contrast, healthy subjects experienced an increase in the expression levels of PPAR-γ after fat overload. Decreased expression of PPAR-γ gene can explain the base concept of "saturation", derived from a limitation in the expandability of fat and peripheral lipid metabolism, in pathophysiological situations. This saturation in lipid balance can lead to lipotoxicity which ends in saturation of the antioxidant machinery and could finally affect the regulation of PPAR-γ expression.

Interestingly, Garcia-Fuentes et al. showed that in a group of morbidly obese persons, plasma SOD activity and mRNA expression of PPAR-γ were decreased after taking a high-fat meal. Also they indicated that PPAR-γ expression after the high-fat meal was correlated with the plasma SOD activity.

It can be hypothesized that the activation of PPAR-γ in our study might favor adipocyte differentiation, resulting in a decrease in the inflammatory status of adipose tissue during obesity. Diet induced obesity is associated with increased inflammatory gene expression in adipose tissue via adipocyte hypertrophy and macrophage infiltration. It has been shown that PPAR-γ is able to reverse macrophage infiltration, and subsequently reduces the expression of inflammatory genes. Moreover, it can be suggested that reactivating PPAR-γ could be a response in order to restore the metabolic balance in MetS.

In our study, the increase in antioxidant parameters showed no significant changes; however, the TOS was significantly higher which could indicate the increase in lipotoxicity.

We did not observe a significant association between expression of the PPAR-γ gene and the oxidative stress status in MetS patients; however, it could be due to the limited number of subjects in this study.

The scientists believe that the contributed mechanisms to the pathogenesis of MetS are still in need of intense investigation. There is an alteration in expression of some genes in MetS that can lead to obesity, diabetes mellitus, and hypertension. Recently we have shown that ABCG1...
gene expression, one of the ABC transmembrane transporters, significantly decreases in MetS.\textsuperscript{35} Down-regulation of ABCG1 can affect cholesterol efflux and predispose patients to atherosclerosis.

Also there are some changes in the expression of some cytokines' genes in MetS. An increase in the expression of the leptin receptor gene and a decrease in the expression of IL-10 and IL-8 have been reported in MetS.\textsuperscript{36,37} On the other hand, no significant changes has been observed in the expression of IL-7.\textsuperscript{37} It is believed that MetS is caused by the chronic activation of the innate immune system, which can contribute to the some components of MetS.\textsuperscript{28} Changes in the above mentioned cytokines, leptin receptors and PPAR-\gamma may play a role in this condition. PPAR-\gamma plays an important role in metabolic balance.

An increase in expression of the PPAR-\gamma gene in subjects with MetS in our results indicates a possible role in the pathogenesis of this disease. This up-regulation of the PPAR-\gamma gene can be a physiologic response to increased resistance to oxidative stress.

ACKNOWLEDGEMENTS

This work was supported by a grant from the Hamadan University of Medical Science. This article is extracted from M. Hatami MSc thesis.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Weiss R, Bremer AA, Lustig RH. What is metabolic syndrome, and why are children getting it? Ann N Y Acad Sci 2013;1281:123-40.  
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.  
3. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-61.  
4. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;1:C'D004996.  
5. Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Cirec J 2006;70:1437-42.  
6. Victor VM, Rocha M, Herance R, Hernandez-Mijares A. Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr Pharm Des 2011;17:3947-58.  
7. Del Ben M, Angelico F, Cangemi R, Loffredo L, Carnevale R, Augelletti T, et al. Moderate weight loss decreases oxidative stress and increases antioxidant status in patients with metabolic syndrome. ISRN Obes 2012;2012:60427.  
8. Dong C, Zhou H, Shen C, Yu LG, Ding Y, Zhang YH, et al. Role of peroxisome proliferator-activated receptors gene polymorphisms in type 2 diabetes and metabolic syndrome. World J Diabetes 2015;6:654-61.  
9. Grygiel-Górniaik B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Nutr J 2014;13:17.  
10. Seok H, Cha BS. Refocusing peroxisome proliferator activated receptor-\alpha: a new insight for therapeutic roles in diabetes. Diabetes Metab J 2013;37:326-32.  
11. Setoguchi K, Misaki Y, Terauchi Y, Yamauchi T, Kawahata K, Kadokawa T, et al. PGC-1alpha modifies peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest 2010;1:108:1667-75.  
12. Klotz L, Schmidt M, Giese T, Sastre M, Knolle P, Klockgether T, et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 2005;175:4948-55.  
13. Stienstra R, Duval C, Mülner M, Kersten S, PPARs, Obesity, and Inflammation. PPAR Res 2007;2007:95974.  
14. Narala VR, Suhrmanani PA, Narasimba VR, Shaid PB, Panati K. The role of nitrored fatty acids and peroxisome proliferator-activated receptor gamma in modulating inflammation. Int Immunopharmacol 2014;23:283-7.  
15. Sharma AM, Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007;92:386-95.  
16. Hoppes E, Noto D, Caimi G, Averna MR. A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis 2010;20:72-7.  
17. Lu B, Moser AH, Shigenaka JK, Feingold KR, Grunfeld C. Type II nuclear hormone receptors, coactivator, and target gene repression in adipose tissue in the acute-phase response. J Lipid Res 2006;47:2179-90.  
18. Kim MS, Sweeney TR, Shigenaka JK, Chui LG, Moser A, Grunfeld C, et al. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Metabolism 2007;56:267-79.  
19. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.  
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.  
21. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.  
22. Benzie IF, Strain JJ. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol 1999;299:15-27.  
205
23. Winterbourn CC, Hawkins RE, Brian M, Carrell RW. The estimation of red cell superoxide dismutase activity. J Lab Clin Med 1975;85:337-41.
24. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-11.
25. Szanto A, Nagy L. The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology 2008;213:789-803.
26. Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 2005;23:393-9.
27. Garcia-Fuentes E, Murri M, Garrido-Sanchez L, Garcia-Serrano S, Garcia-Almeida JM, Moreno-Santos I, et al. PPARgamma expression after a high-fat meal is associated with plasma superoxide dismutase activity in morbidly obese persons. Obesity (Silver Spring) 2010;18:952-8.
28. Nunn AV, Bell J, Barter P. The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance. Nucl Recept 2007;5:1.
29. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007;47:142-56.
30. Hwang J, Kleinhenz DJ, Lassègue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 2005;288:C899-905.
31. Macias-Gonzalez M, Cardona F, Queipo-Ortuño M, Bernal R, Martín M, Tinahones FJ. PPARgamma mRNA expression is reduced in peripheral blood mononuclear cells after fat overload in patients with metabolic syndrome. J Nutr 2008;138:903-7.
32. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 2007;3:e64.
33. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30.
34. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med 2011;9:48.
35. Tavoosi Z, Moradi-Sardareh H, Saidijam M, Yadegarazari R, Borzuei S, Soltanian A, et al. Cholesterol Transporters ABCA1 and ABCG1 Gene Expression in Peripheral Blood Mononuclear Cells in Patients with Metabolic Syndrome. Cholesterol 2015;2015:682904.
36. Tootoonchi AS, Goodarzi MT, Hassanzadeh T, BorzueiSh, Yadegarazari R, Shabab N, et al. The expression of interleukins 10 and leptin receptor in peripheral mononuclear cells from patients with metabolic syndrome. J Basic Appl Sci Res 2012;2:10055-62.
37. Saidijam M, Tootoonchi AS, Goodarzi MT, Hassanzadeh T, Borzuei Sh, Yadegarazari R, et al. Expression of interleukins 7 & 8 in peripheral blood mononuclear cells from patients with metabolic syndrome: a preliminary study. Indian J Med Res 2014;140:238-43.